Size | Price | Stock | Qty |
---|---|---|---|
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Betahistine dihydrochloride (formerly PT 9; PT9; trade names Veserc, Serc, Hiserk, Betaserc, Vergo), the dihydrochloride salt of Betahistine which was pproved in EU in 1970s for treating Ménière's disease, is a potent antagonist of histamine H3 receptor used as an anti-vertigo drug. It inhibits the histamine H3 receptor with an IC50 of 1.9 μM. Betahistine has been prescribed frequently to treat balance issues or to lessen the symptoms of vertigo linked to Ménière's disease.
Targets |
Histamine H3 receptor ( IC50 = 1.9 μM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Animal Protocol |
Collagen-induced arthritis (CIA) DBA/1 male mouse model
1 mg/kg; 5mg/kg Oral adminstration; day 21 to day 42 after a 21-day CIA induction |
|
References |
|
Molecular Formula |
C8H12N2.2HCL
|
---|---|
Molecular Weight |
209.12
|
Exact Mass |
208.05
|
Elemental Analysis |
C, 45.95; H, 6.75; Cl, 33.90; N, 13.40
|
CAS # |
5579-84-0
|
Related CAS # |
Betahistine; 5638-76-6; Betahistine-d3 dihydrochloride; 244094-72-2; Betahistine mesylate; 54856-23-4; Betahistine-13C,d3 dihydrochloride
|
Appearance |
Solid powder
|
SMILES |
CNCCC1=CC=CC=N1.Cl.Cl
|
InChi Key |
XVDFMHARQUBJRE-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C8H12N2.2ClH/c1-9-7-5-8-4-2-3-6-10-8;;/h2-4,6,9H,5,7H2,1H3;2*1H
|
Chemical Name |
N-methyl-2-pyridin-2-ylethanamine;dihydrochloride
|
Synonyms |
PT-9; Betahistine dihydrochloride; Betahistine HCl; PT 9; PT9; trade names Veserc, Serc; Hiserk; Betaserc; Vergo
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 150 mg/mL (717.29 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.7819 mL | 23.9097 mL | 47.8194 mL | |
5 mM | 0.9564 mL | 4.7819 mL | 9.5639 mL | |
10 mM | 0.4782 mL | 2.3910 mL | 4.7819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00160238 | Completed | Drug: Betahistine 24 mg bid (Betaserc) |
Meniere's Disease | Solvay Pharmaceuticals | January 2003 | Phase 4 |
NCT00459992 | Completed | Drug: Betahistine Hydrochloride | Obesity Overweight |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
April 10, 2007 | Phase 1 |
NCT05938517 | Completed | Drug: Betahistine dihydrochloride Drug: Selegiline-hydrochloride |
Ménière's Disease | Ludwig-Maximilians - University of Munich |
June 2, 2021 | Phase 1 |
NCT01468285 | Completed | Drug: betahistine dihydrochloride Other: placebo |
Gait or Balance Disorder Problems | Abbott Products | February 2012 | Phase 4 |
NCT00829881 | Completed | Drug: Betahistine Hydrochloride Drug: Placebo Capsule |
Attention Deficit Disorder With Hyperactivity |
P2D, Inc. | January 2009 | Phase 1 |